You are here: Industry Insights > Cell Therapy

News List

Xiangxue Pharma to build cell therapy facility biospectrumasia
June 11, 2018
XPH is focused on cancer treatments based on a new-generation TCR T-cell therapy.
Celixir’s cell therapy gets green light for heart failure trial pharmatimes
January 10, 2018
The Medicines and Healthcare Products Regulatory Agency has issued a green light allowing Celixir to carry out a potentially pivotal Phase IIb human clinical trial with its stem cell therapy Heartcel.
Stem cell therapy fails to improve symptoms of peripheral artery disease pharmafile
November 17, 2017
A new study has revealed that a promising stem cell therapy failed to improve ability to walk in patients with peripheral artery disease (PAD), a condition that causes pain or weakness in the legs due to atherosclerotic blockages in the legs.
Stem cell therapy shows promise for macular degeneration europeanpharmaceuticalreview
November 16, 2017
Studies show cell-based treatment is safe in patients with dry macular degeneration, with one showing improved vision…
Repairing broken hearts with injectable patches fiercebiotech
August 15, 2017
Patches small enough to be injected with a needle are showing promise for repairing damaged hearts.
Sartorius and Science Magazine to Award Prize for Regenerative Medicine and Cell Therapy biospectrumasia
June 28, 2017
Sartorius together with the renowned Science magazine will award a Sartorius & Science Prize for Regenerative Medicine & Cell Therapy.
Orchard Inks Mfg. Agreement with PCT Cell Therapy contractpharma
June 06, 2017
Orchard Therapeutics has entered a clinical manufacturing services agreement with PCT Cell Therapy Services, a provider of contract services for the development and manufacture of cell-based therapeutic and regenerative medicine products.
Orchard Therapeutics signs manufacturing services agreement with PCT Cell Therapy Services cphi-online
June 02, 2017
Under the terms of this new agreement, PCT will provide GMP-compliant manufacturing services for Orchard’s lead product, OTL-101, an autologous ex-vivo gene therapy for the treatment of ADA-SCID.
Orchard Therapeutics Ltd. announces manufacturing services agreement with PCT Cell Therapy Services biospectrumasia
May 31, 2017
Under the terms of this new agreement, PCT will provide GMP-compliant manufacturing services for Orchard’s lead product, OTL-101
UK’s Innovation Agency Backs Plasticell contractpharma
April 14, 2017
Cell therapy producer will make red blood cell substitute from pluripotent stem cells

Previous page 1 2 3 4 5 6 7 8 Next page